Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "neurological-disorders"

17 News Found

Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease
News | January 04, 2025

Nano-formulation of darkness hormone could be therapeutic solution for Parkinson's disease

Parkinson's disease (PD) is one of the most common neurological disorders caused by the death of dopamine-secreting neurons in the brain


DKSH and Abcam join forces to advance life science research in Vietnam
Supply Chain | November 19, 2024

DKSH and Abcam join forces to advance life science research in Vietnam

This partnership is set to meet the growing demand for innovative life science research solutions in the Vietnamese market


AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia
News | November 14, 2024

AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline


Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test
News | October 21, 2024

Sunbird Bio raises additional US $14 million to advance Alzheimer blood tech test

Financing includes new funding from leading global organizations Eli Lilly and Company and EDBI


Heuron gets FDA green light for stroke triage and notification solution
News | May 25, 2024

Heuron gets FDA green light for stroke triage and notification solution

This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea


Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease
Diagnostic Center | March 03, 2024

Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease

Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg


MIRA Pharmaceuticals announces collaboration with Pharmaseed
News | February 08, 2024

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024


Mandaviya inaugurates new facilities at NIMHANS and launches new logo of Tele-MANAS
Healthcare | October 11, 2023

Mandaviya inaugurates new facilities at NIMHANS and launches new logo of Tele-MANAS

Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells


Novartis acquires DTx Pharma to develop siRNA therapies
News | July 19, 2023

Novartis acquires DTx Pharma to develop siRNA therapies

Deal includes DTx-1252, a potential therapy for the neuromuscular disorder Charcot-Marie-Tooth disease type 1A (CMT1A), and two additional preclinical programs for other neuroscience indications